LEVICK | February 9th, 2021
Bridging the “Preclinical Gap” in Childhood Cancer Research

Hello darkness, my old friend,
I’ve come to talk with you again.
Because a vision softly creeping,
Left its seeds while I was sleeping.
And the vision that was planted in my brain,
Still remains,
Within the sound of silence.
― Paul Simon
Most of the time we are overwhelmed by an avalanche of communications – more information in a day than our parents received in a year; more in a year than our grandparents received in a lifetime. We get just too much information, often about too few things, to the point all we can do is literally categorize, not understand. What is the cost to the issues that can’t cut through this clutter? One of the most important issues that receives little attention and precious little funding is childhood cancer. Children’s Cancer Therapy Development Institute (cc-TDI) is here to change that.
I have the privilege of sitting on the board and being part of a team at our firm that does pro-bono work for cc-TDI. It’s a nonprofit determined to ensure that promising drugs are sent into clinical trials, especially for the most dangerous of childhood cancers. To laypeople, a “preclinical gap” in the prevention and treatment of a disease sounds innocuous – something that ought to be easily resolved, certainly not something that involves issues of life-and-death. But to medical professionals or to the parents of kids with cancer, a preclinical gap is a heartbreaking and oppressive reality. Sadly, the preclinical gap in childhood cancer research contributes to thousands of avoidable deaths every year in the U.S. and across the world.
Here’s why the nonprofit cc-TDI is so focused on bridging the chasm between research and treatment in childhood cancer. Despite breakthroughs in research laboratories, many forms of childhood cancer have seen little to no advancement in treatment options for the past three decades. The system contains a huge glitch: pathbreaking new discoveries are made in research labs, but they are rarely if ever translated into new treatments for children.
Why? It comes down to the metrics of pharmaceutical marketing. Thank heavens the universe of children with cancer, although tragic in every sense, remains (relatively) small. For the pharmaceutical industry, the process of turning a scientific discovery into a new treatment is tedious and time-consuming; it generally does not generate significant profits – unless, of course, the potential marketplace acts to spur preclinical (preliminary) and clinical trials.
cc-TDI is determined to provide that spur. Its research team is exploring and testing state-of-the-art treatment options for the most urgent issues facing children with cancer. As cc-TDI’s Scientific Director, Dr. Charles Keller, observed in a recent interview, “The mission is simple. We just want to make all childhood cancer universally survivable.”
The example of Megan Bugg, a childhood cancer survivor and cc-TDI team member, illustrates the urgency of closing the gap in childhood cancer research. For six years, 19-year-old Megan Bugg has fought a rare form of skeletal muscle cancer known as alveolar rhabdomyosarcoma. Somehow, she’s endured four relapses, some 117 weeks of chemotherapy and more than 130 radiation treatments. She’s helped crowdfund $212,000 to underwrite research that could enable a national clinical trial in which she can enroll.
“Through my experiences I have become a passionate advocate for childhood cancer research,” Megan says. “My personal goal is to make sure no more kids have to experience what I have experienced.”
Another inspirational example is Calleigh Germer of Tigard, Oregon, who promised her terminally ill 11-year-old friend that she would devote her life to finding a cure for her friend’s cancer. Three years later, Calleigh is the 14-year-old chairperson of the cc-TDI Junior Board of Directors.
Powerful stories of sacrifice and resolve abound throughout cc-TDI. They all point to the need to fix the hole in the system, to get promising childhood cancer research into preclinical trials so that young people can get the treatment they need to get better.
It has been my honor to serve on cc-TDI’s board of directors. When I hear the frustrations of pediatric cancer researchers about not getting their potential breakthroughs to patients, I can’t help but think the same thing that so many Americans feel these days: “C’mon. We’re better than this.”
To find out about what you can do strengthen childhood cancer research and prevention, visit www.cc-tdi.org, email info@cc-tdi.org or call (503) 985-6010.
Richard Levick
LEVICK | February 9th, 2021
Bridging the “Preclinical Gap” in Childhood Cancer Research

Hello darkness, my old friend,
I’ve come to talk with you again.
Because a vision softly creeping,
Left its seeds while I was sleeping.
And the vision that was planted in my brain,
Still remains,
Within the sound of silence.
― Paul Simon
Most of the time we are overwhelmed by an avalanche of communications – more information in a day than our parents received in a year; more in a year than our grandparents received in a lifetime. We get just too much information, often about too few things, to the point all we can do is literally categorize, not understand. What is the cost to the issues that can’t cut through this clutter? One of the most important issues that receives little attention and precious little funding is childhood cancer. Children’s Cancer Therapy Development Institute (cc-TDI) is here to change that.
I have the privilege of sitting on the board and being part of a team at our firm that does pro-bono work for cc-TDI. It’s a nonprofit determined to ensure that promising drugs are sent into clinical trials, especially for the most dangerous of childhood cancers. To laypeople, a “preclinical gap” in the prevention and treatment of a disease sounds innocuous – something that ought to be easily resolved, certainly not something that involves issues of life-and-death. But to medical professionals or to the parents of kids with cancer, a preclinical gap is a heartbreaking and oppressive reality. Sadly, the preclinical gap in childhood cancer research contributes to thousands of avoidable deaths every year in the U.S. and across the world.
Here’s why the nonprofit cc-TDI is so focused on bridging the chasm between research and treatment in childhood cancer. Despite breakthroughs in research laboratories, many forms of childhood cancer have seen little to no advancement in treatment options for the past three decades. The system contains a huge glitch: pathbreaking new discoveries are made in research labs, but they are rarely if ever translated into new treatments for children.
Why? It comes down to the metrics of pharmaceutical marketing. Thank heavens the universe of children with cancer, although tragic in every sense, remains (relatively) small. For the pharmaceutical industry, the process of turning a scientific discovery into a new treatment is tedious and time-consuming; it generally does not generate significant profits – unless, of course, the potential marketplace acts to spur preclinical (preliminary) and clinical trials.
cc-TDI is determined to provide that spur. Its research team is exploring and testing state-of-the-art treatment options for the most urgent issues facing children with cancer. As cc-TDI’s Scientific Director, Dr. Charles Keller, observed in a recent interview, “The mission is simple. We just want to make all childhood cancer universally survivable.”
The example of Megan Bugg, a childhood cancer survivor and cc-TDI team member, illustrates the urgency of closing the gap in childhood cancer research. For six years, 19-year-old Megan Bugg has fought a rare form of skeletal muscle cancer known as alveolar rhabdomyosarcoma. Somehow, she’s endured four relapses, some 117 weeks of chemotherapy and more than 130 radiation treatments. She’s helped crowdfund $212,000 to underwrite research that could enable a national clinical trial in which she can enroll.
“Through my experiences I have become a passionate advocate for childhood cancer research,” Megan says. “My personal goal is to make sure no more kids have to experience what I have experienced.”
Another inspirational example is Calleigh Germer of Tigard, Oregon, who promised her terminally ill 11-year-old friend that she would devote her life to finding a cure for her friend’s cancer. Three years later, Calleigh is the 14-year-old chairperson of the cc-TDI Junior Board of Directors.
Powerful stories of sacrifice and resolve abound throughout cc-TDI. They all point to the need to fix the hole in the system, to get promising childhood cancer research into preclinical trials so that young people can get the treatment they need to get better.
It has been my honor to serve on cc-TDI’s board of directors. When I hear the frustrations of pediatric cancer researchers about not getting their potential breakthroughs to patients, I can’t help but think the same thing that so many Americans feel these days: “C’mon. We’re better than this.”
To find out about what you can do strengthen childhood cancer research and prevention, visit www.cc-tdi.org, email info@cc-tdi.org or call (503) 985-6010.
Richard Levick
- Brand
- Should Companies Consider Appointing Chief Paranoia Officers to Combat Disinformation?
- Can Capitalism Really Be “For Humanity?”
- The Fifth Estate: A Business Guide for Surviving “The Troubles”
- Here We Come
- Corporate Revolt Over Campaign Donations Shakes Political World
- What Happens Next?
- CSR & Sustainability
- Public Perception & the Biden Transition
- WATCH: Reputation Management with PRSA
- Over the River and Through The Woods
- Why Non-Profits are so Vulnerable to Crisis Risk
- The Threat to Free Markets
- Communications
- The Regulatory Hall of Fame
- Should Companies Consider Appointing Chief Paranoia Officers to Combat Disinformation?
- The Day the Music Died
- “Crooked Dominion Machines,” Impeachments, Insurrections & The First 100 Days
- Reflections on a Turbulent Year: 2020
- The Fifth Estate: A Business Guide for Surviving “The Troubles”
- Here We Come
- The Ministry of Common Sense
- Why Should I Apologize? Lawyers vs. Communicators
- What Happens Next?
- CSR & Sustainability
- A Conversation with Abbe Lowell
- Company News
- Reflections on a Turbulent Year: 2020
- Here We Come
- Recent Awards & Recognition
- Won’t You Be My Neighbor?
- What’s a Director to Do?
- LEVICK Announces Partnership with BCG
- A New Look
- Albert Krieger, 1923-2020
- LEVICK Announces Partnership with Jipyong
- Speaking to In-House Counsel
- Childhood Lessons
- LEVICK Announces New Webinar Series with Turbine Labs
- Crisis
- The Regulatory Hall of Fame
- Should Companies Consider Appointing Chief Paranoia Officers to Combat Disinformation?
- The Price of Courage
- Bridging the “Preclinical Gap” in Childhood Cancer Research
- The Day the Music Died
- GameStop: The Buck Starts Here
- The Risk of CEO Activism
- Top Crises of 2020
- “Crooked Dominion Machines,” Impeachments, Insurrections & The First 100 Days
- Reflections on a Turbulent Year: 2020
- 3 Tech Lessons Businesses Must Learn From COVID-19
- Trump’s pardons undercut a decade of foreign lobbying law enforcement. What now?
- Finance
- Can Capitalism Really Be “For Humanity?”
- GameStop: The Buck Starts Here
- Here We Come
- The Threat to Free Markets
- Advisory & Insurance Services
- WATCH: Revolutionizing Litigation Finance
- Litigation Finance: Revolutionizing Litigation
- Consumer-Focused Solutions for Financial Health
- Event: Consumer-Focused Solutions for Financial Health
- Sports: Power and Money in a New Age of Social Justice
- The Balancing Act: The Role of Whistleblowers in American Commerce and Government
- The Evolving and More Powerful FARA
- Guest Column
- Guest Blog: The Mainstream Media Gets an A for Intellectual Arrogance, an F for Journalism
- Buckle up Directors: Cybersecurity Risk and Bankruptcy Risk Are Not Mutually Exclusive
- Buckle up Directors: Cybersecurity Risk and Bankruptcy Risk Are Not Mutually Exclusive
- South Africa: The Slow Decline of the ANC
- Why CSR Fails and How to Fix It
- What to Expect Following the European Elections?
- Buhari Inaugurated. What Now for Nigeria?
- Marketing- It’s Up To You…
- Crisis Management lessons from the air-crash investigation model
- The Future of War
- Health
- Reflections on a Turbulent Year: 2020
- Food Issues & the Biden Administration
- Covid-19: The Pandemic that Never Should Have Happened
- Pharma’s Post-Pandemic Policy Outlook
- Keeping Hope Alive
- Real Herd Immunity
- The Fiction of College Sports Amateurism
- Mac Summit: Crisis Communications in a Post-Covid, Post-Election World
- Travel Industry Communications in the Age of Covid-19
- Track of Time
- Is C-19 Taking Women Lawyers’ Careers Back to the 1950s?
- Post-Pandemic PR Strategy
- In Memoriam
- Snider’s Super Foods: Locally World Famous
- Speak Truth With Love, Not Anger
- In Memoriam: Stephen Susman
- Letter to the Movement
- John Lewis’ Life Bridged the Best of America
- Albert Krieger, 1923-2020
- In Memoriam of Marcia Horowitz
- Jim Lehrer Passes Away
- Martin Luther King, Jr.
- Harold Burson Passes Away
- Interviews
- CommPRO: Ruth Bader Ginsberg’s Life & Legacy
- Richard Levick on “My Wakeup Call”
- Primerus Webinar: Into the Wind
- The Future of Baseball Post-Pandemic
- Webinar: The End of Brand Neutrality
- Thought Leadership & Organic Growth
- Man & Superman
- LEVICK Announces New Webinar Series with Turbine Labs
- Navigating Coronavirus Challenges in the Insurance Industry
- VIDEO: How to Anticipate & Avoid a Crisis
- What’s Next? with Julie Chase
- What’s Next?: California Electoral Behavior
- Law Firms
- Fighting for the Rule of Law with Marshall Harris
- Why Should I Apologize? Lawyers vs. Communicators
- You Took a PPP Loan. Now Get Ready to Talk About It.
- Beyond Black Swan: Positioning the law firm for the new normal
- A Salute to Personal Courage and the Rule of Law
- Cyber Risk Institute Expands Its Profile
- When a client becomes a law firm’s PR nightmare
- The General Counsel’s Dilemma
- A First Look at the Google Antitrust Suit
- The Latest Top Class Actions
- Trust on Trial: How Communicators Succeed in a World No Longer Trusted
- The Latest Settlements, Class actions, Investigations & More
- Litigation
- Buyers’ Guide to In-House Tech
- Fighting for the Rule of Law with Marshall Harris
- Why Should I Apologize? Lawyers vs. Communicators
- A Conversation with Abbe Lowell
- Leveraging Legal Expertise in Communications
- You Took a PPP Loan. Now Get Ready to Talk About It.
- Beyond Black Swan: Positioning the law firm for the new normal
- A Salute to Personal Courage and the Rule of Law
- Cyber Risk Institute Expands Its Profile
- When a client becomes a law firm’s PR nightmare
- The General Counsel’s Dilemma
- WATCH: Revolutionizing Litigation Finance
- Our Work
- Bridging the “Preclinical Gap” in Childhood Cancer Research
- Recent Awards & Recognition
- The Cyber Bad Guys Are Getting Worse
- Crisis Communications & The Age of Cancel Culture
- Standing on the Shoulders of Giants
- Video: Conversations with American Legends
- Staying Ahead of the Crisis
- A New Era of Insurance Marketing
- Infographic: Judgment Free Zone
- Infographic: Barriers to Entry
- Infographic: History Meter
- Assistance for Law Firms Engaged in Pro Bono
- Public Affairs
- The Regulatory Hall of Fame
- Richard Levick on U.S.-China Relations
- The Price of Courage
- Can Capitalism Really Be “For Humanity?”
- GameStop: The Buck Starts Here
- Impeach, Indict, Heal? A Discussion of Post-Trump Washington
- “Crooked Dominion Machines,” Impeachments, Insurrections & The First 100 Days
- Trump’s pardons undercut a decade of foreign lobbying law enforcement. What now?
- Fighting for the Rule of Law with Marshall Harris
- The Fifth Estate: A Business Guide for Surviving “The Troubles”
- What to expect as the clock approaches midnight
- How to Stop the Madness
- Risk
- Should Companies Consider Appointing Chief Paranoia Officers to Combat Disinformation?
- The Price of Courage
- Ingredients of Decency
- ESG Performance and Credit Markets
- The Coronavirus Saga is Just Beginning
- No. 1 Risk of the Decade
- The Risk Evolution of Corporate Risk
- Extend Risk Management Reach
- Collective Action
- Risk Identifying Software
- The New Risk of Doing Nothing
- Political Unrest In Hong Kong
- Social
- Should Companies Consider Appointing Chief Paranoia Officers to Combat Disinformation?
- The Price of Courage
- Bridging the “Preclinical Gap” in Childhood Cancer Research
- The Ministry of Common Sense
- How to Stop the Madness
- A Remembrance of Tommy Raskin
- No ‘justice’ in rep’s vote
- A Call for Orderly & Peaceful Transition of Power
- Recovering from the Greatest Sacrifice
- CSR & Sustainability
- A New Year’s Resolution
- Dropping the Mic
- Technology
- Should Companies Consider Appointing Chief Paranoia Officers to Combat Disinformation?
- Bridging the “Preclinical Gap” in Childhood Cancer Research
- 3 Tech Lessons Businesses Must Learn From COVID-19
- Constella Intelligence Announces Hunter for Improved Investigation Capability
- Cyber Risk Institute Expands Its Profile
- Digital Politics: The Future of Voting Technology
- Ethics in Electronics
- The Cyber Bad Guys Are Getting Worse
- A First Look at the Google Antitrust Suit
- The Pause
- Cybersecurity Incidents of the Summer
- The Changing Digital Economy and Cyber Risks
- This Week
- A Remembrance of Tommy Raskin
- A New Year’s Resolution
- Over the River and Through The Woods
- Dropping the Mic
- Won’t You Be My Neighbor?
- The Cyber Bad Guys Are Getting Worse
- What We Hear
- Track of Time
- Video: Conversations with American Legends
- Conversations with American Legends
- A New Era of Insurance Marketing
- American Legend